Results 161 to 170 of about 7,679 (193)

Real-World Effectiveness of Biologic Therapies for Severe Asthma in a Diverse Middle Eastern Cohort: Evaluation of Longitudinal Symptom Improvement. [PDF]

Cureus
Kareem MA, Naqvi SZ, Ammar Husain S, Cruz LGD, Husain SA.   +4 more
europepmc   +1 more source

Straight to Phase III: Model-Informed Approach Speeds Depemokimab Clinical Development in Interleukin-5-Driven Diseases. [PDF]

Clin Pharmacol Ther
Zecchin C, Schalkwijk S, Pouliquen IJ, Berges A, Bird N, Follows R, Austin D.   +6 more
europepmc   +1 more source

One size does not fit all: uncontrolled T2 inflammation on tezepelumab-a case series. [PDF]

Allergy Asthma Clin Immunol
Tardif A, Boulay ME, Côté A, Godbout K.   +3 more
europepmc   +1 more source

Biologic Therapies: A Systematic Review of the Indications, Efficacy, Safety, and Outcomes in Ear, Nose, and Throat Diseases. [PDF]

Cureus
Al Saloom Z, Alawainati M, Abdeen Z, Qadmi I, Mandeel A, AlAani K.   +5 more
europepmc   +1 more source

Clinical Remission in Severe T2-High Asthma in Real Life After Anti-IgE, Anti-IL-5 and Anti-IL5R: A Potential Role for CRP as a Biomarker. [PDF]

Clin Transl Allergy
Vervier J, Sabbe M, Louis F, Moermans C, Guissard F, Sanchez C, Paulus V, Henket M, Philippe G, Beijnink CWH, Bridevaux PO, Schleich F, Louis R.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mepolizumab

Reactions Weekly, 2022
  +10 more sources

Mepolizumab

Reactions Weekly, 2017
Mepolizumab ist ein monoklonaler Antikörper, der für schwere Fälle eines sogenannten eosinophilen Asthmas bronchiale vorgesehen ist und das Risiko einer Exazerbation zu vermindern vermag. Der Stellenwert des Medikamentes ist aber, auch wegen des ausserordentlich hohen Preises, noch nicht definiert.
  +4 more sources

Mepolizumab

Reactions Weekly, 2023
  +5 more sources

Mepolizumab

Reactions Weekly, 2018
  +7 more sources